BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29540850)

  • 21. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of serum cytokines and soluble HLA-G levels in children with leukemia who undergo allogeneic stem cell transplantation.
    Kaya Z; Yüce D; Kirkiz S; Koçak Ü; Ozmen F
    Cytokine; 2022 May; 153():155869. PubMed ID: 35358902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-E polymorphism and clinical outcome after allogeneic hematopoietic stem cell transplantation in Egyptian patients.
    Mossallam GI; Fattah RA; El-Haddad A; Mahmoud HK
    Hum Immunol; 2015 Mar; 76(2-3):161-5. PubMed ID: 25543014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites.
    Lazana I; Zoudiari A; Kokkinou D; Themeli M; Liga M; Papadaki H; Papachristou D; Spyridonidis A
    Haematologica; 2012 Sep; 97(9):1338-47. PubMed ID: 22419574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D
    Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
    Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.
    Schneider M; Munder M; Karakhanova S; Ho AD; Goerner M
    Clin Lab Haematol; 2006 Dec; 28(6):382-90. PubMed ID: 17105491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
    Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-transplant donor CD4
    Rubio MT; Bouillié M; Bouazza N; Coman T; Trebeden-Nègre H; Gomez A; Suarez F; Sibon D; Brignier A; Paubelle E; Nguyen-Khoc S; Cavazzana M; Lantz O; Mohty M; Urien S; Hermine O
    Leukemia; 2017 Apr; 31(4):903-912. PubMed ID: 27740636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Applications of monitoring human leukocyte antigen G and its inhibitory receptors in post-renal transplantation].
    XIAO L; SHI BY; GAO Y; CAI M; Qian YY; HE XY; XU XG; HAN Y; ZHOU WQ; MENG XY; HAN MX
    Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(36):2524-7. PubMed ID: 21092455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
    Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
    Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
    Alsahebfosoul F; Zavaran Hosseini A; Salehi R; Etemadifar M; Esmaeil N; Jamshidian A
    Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):298-305. PubMed ID: 26546899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
    Rutten CE; van Luxemburg-Heijs SA; Halkes CJ; van Bergen CA; Marijt EW; Oudshoorn M; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):40-8. PubMed ID: 22871556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.